CNMD — CONMED Corporation

Summary of CONMED Corporation Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Sales: $373.2 million, up 7.9% year-over-year (7.1% in constant currency).
• Full-Year Sales: $1.375 billion, up 5.2% year-over-year (5.1% in constant currency).
• Adjusted EPS: Q4 at $1.43 (up 6.7%); Full-year at $4.59 (up 10.1%).
• GAAP Net Income: Q4 at $16.7 million ($0.54 per share) compared to $33.8 million ($1.00 per share) in Q4 2024; Full-year at $47.1 million ($1.51 per share) vs. $132.4 million ($4.25 per share) in 2024.
• Adjusted Gross Margin: Q4 at 56.6%, down 100 basis points; Full-year at 56.4%, up 10 basis points.
• Leverage Ratio: 2.9 times as of year-end.
• Cash Flow from Operations: Q4 at $46.3 million; Full-year at $170.7 million.

2. Strategic Updates and Business Highlights

• Portfolio Review: CONMED announced the exit from gastroenterology product lines to focus on high-growth areas, expected to improve long-term margins by approximately 80 basis points.
• Supply Chain Improvements: Significant progress made in resolving supply chain constraints, leading to a three-year low in backorder value.
• Growth Platforms:
  • AirSeal: Used in 1.6 million procedures in 2025, with expectations for continued growth in robotic and laparoscopic surgery.
  • Buffalo Filter: Positioned for growth in the surgical smoke evacuation market, supported by new legislation and product innovations.
  • BioBrace: Gaining traction in sports medicine with increasing adoption across various procedures and positive clinical outcomes.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected between $1.345 billion and $1.375 billion, reflecting organic growth of 4.5% to 6%.
• Adjusted EPS Guidance: Projected between $4.30 and $4.45, factoring in headwinds from the GI exit and tariffs.
• Adjusted Gross Margin Improvement: Anticipated net improvement of 50 to 100 basis points despite tariff impacts.
• Operating Cash Flow: Expected between $145 million and $155 million with capital expenditures of $20 to $30 million.

4. Bad News, Challenges, or Points of Concern

• US General Surgery Sales Decline: Q4 US general surgery sales down 0.4%, affected by strategic portfolio management and exit from non-focus areas.
• GAAP Net Income Decline: Significant drop in GAAP net income compared to the previous year, raising concerns about profitability.
• Tariff Impacts: Expected headwinds from tariffs projected to affect margins and earnings.
• Supply Chain Goals: While improvements noted, the company is still not at its goal of a world-class supply chain.

5. Notable Q&A Insights

• CFO Transition: Todd W. Garner will remain through the transition to a new CFO, emphasizing continuity and stability.
• Market Dynamics: Discussion on the different growth trends in US vs. international markets, with international showing stronger growth.
• M&A Strategy: CONMED remains open to M&A opportunities but is also focusing on organic investments in R&D.
• AirSeal Growth Confidence: Management expressed confidence in AirSeal's growth potential despite recent deceleration, citing underpenetration in laparoscopic procedures as a significant opportunity.

Overall, CONMED Corporation demonstrated solid growth in Q4 2025, with strategic initiatives aimed at enhancing long-term profitability despite facing challenges in certain segments and external pressures from tariffs. The company is optimistic about its growth platforms and operational improvements moving forward.